Search results for "Glycogen Storage Disease"

showing 10 items of 26 documents

Resting Energy Expenditure and Substrate Oxidation in Malnourished Patients With Type 1 Glycogenosis.

2019

Abstract Context Type 1a and 1b glycogenosis [glycogen storage disorder (GSD)1a, GSD1b] are rare diseases generally associated with malnutrition. Although abnormal substrate oxidation rates and elevated energy expenditures might contribute to malnutrition, this issue has not been investigated. Objective To investigate whether abnormal resting energy expenditure (REE) and substrate oxidation rate characterize patients with GSD1. Design Cross-sectional study Setting Outpatient referral center for rare diseases and laboratory of clinical nutrition at the University Hospital of Palermo Patients Five consecutive patients with GSD1 (4 type a, 1 type b; 3 men, 2 women; age range, 19 to 49 years) M…

0301 basic medicineAdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismClinical nutritionmalnoutritionGlycogen Storage Disease Type IProtein oxidationBiochemistryGastroenterology03 medical and health sciencesBasal (phylogenetics)chemistry.chemical_compoundYoung Adult0302 clinical medicineEndocrinologyOxygen ConsumptionLipid oxidationsubstrate oxidationInternal medicineMedicineHumansResting energy expenditureSettore MED/49 - Scienze Tecniche Dietetiche ApplicateResting energy expenditureGlycogenbusiness.industryBiochemistry (medical)MalnutritionCalorimetry IndirectCarbohydratetype 1 glycogenosis.Middle Agedmedicine.diseaseMalnutrition030104 developmental biologyEndocrinologyCross-Sectional StudieschemistryBody CompositionFemalebusinessEnergy MetabolismOxidation-ReductionThe Journal of clinical endocrinology and metabolism
researchProduct

Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease.

2018

Abstract Pompe disease is an autosomal recessive disorder caused by a deficiency of acid α-glucosidase. In addition to the severe infantile form with cardiac involvement, late-onset variants can affect older children, adolescents (aged >1 year old) or adults. Patients with juvenile (a subgroup of late-onset type) Pompe disease typically do not have cardiac alterations e.g. hypertrophic cardiomyopathy, and the diagnosis is often difficult because it can clinically resemble myriad other neuromuscular disorders. A high level of clinical suspicion is necessary for a timely and accurate diagnosis. We describe 3 interesting cases of patients with juvenile-onset Pompe disease who presented some un…

0301 basic medicineMalePediatricsmedicine.medical_specialtyAdolescentDevelopmental DisabilitiesDisease03 medical and health sciences0302 clinical medicinemedicineJuvenileHumansMuscle SkeletalGenetics (clinical)business.industryGlycogen Storage Disease Type IIGenetic variantsalpha-Glucosidases030104 developmental biologyJuvenile onsetNeurologyPediatrics Perinatology and Child HealthMutationNeurology (clinical)Glucan 14-alpha-Glucosidasebusiness030217 neurology & neurosurgeryNeuromuscular disorders : NMD
researchProduct

Mutation analysis in myophosphorylase deficiency (McArdle's disease).

1998

Inherited deficiency of myophosphorylase leads to glycogen storage disease type V (McArdle's disease). We performed mutation analysis in 9 patients of eight unrelated families from Germany with typical cliniclal presentation of myophos-phorylase deficiency. Beside previously described mutations we identified four novel mutations in the myophorsphorylase gene. Four patients were homozygous for a nonsense mutation Arg49Stop that has been reported to be the most common mutation in white patients. Two affected siblings were compound heterozygotes for a novel missense mutation Gly685Arg and the nonsense mutation Arg49Stop. One patient carried a novel nonsense mutation Arg575Stop and a previously…

AdultMaleAdolescentNonsense mutationDNA Mutational AnalysisBiologyCompound heterozygosityPolymerase Chain ReactionmedicineMissense mutationHumansAmino Acid SequenceChildCodonAgedGeneticsTransition (genetics)Base SequenceHomozygoteMiddle Agedmedicine.diseaseNeurologyMyophosphorylaseMutation (genetic algorithm)MutationMutation testingGlycogen Storage Disease Type VFemaleNeurology (clinical)Glycogen storage disease type VPolymorphism Restriction Fragment LengthAnnals of neurology
researchProduct

Mycotoxin Dietary Exposure Assessment through Fruit Juices Consumption in Children and Adult Population

2019

Consumption of fruit juice is becoming trendy for consumers seeking freshness and high vitamin and low caloric intake. Mycotoxigenic moulds may infect fruits during crop growth, harvest, and storage leading to mycotoxin production. Many mycotoxins are resistant to food processing, which make their presence in the final juice product very likely expected. In this way, the presence of 30 mycotoxins including aflatoxin B1 (AFB1), aflatoxin B2 (AFB2), aflatoxin G1 (AFG1), aflatoxin G2 (AFG2), alternariol (AOH), alternariol monomethyl ether (AME), Ochratoxin A (OTA), fumonisin B1 (FB1), fumonisin B2 (FB2), enniatin A (ENNA), enniatin A1 (ENNA1), enniatin B (ENNB), enniatin B1 (ENNB1), beauverici…

AdultMaleOchratoxin ACitrusAflatoxinLiquid Phase MicroextractionHealth Toxicology and Mutagenesislcsh:MedicineFood ContaminationBiologyToxicologyfruit juice01 natural sciencesArticleDietary ExposurePatulinGlycogen Storage Disease Type IIIchemistry.chemical_compound0404 agricultural biotechnologyTandem Mass SpectrometryHumansFood scienceChildMycotoxinFumonisin B2DLLMElcsh:R010401 analytical chemistryReproducibility of Resultsrisk assessment04 agricultural and veterinary sciencesMycotoxins040401 food scienceBeauvericin0104 chemical sciencesFruit and Vegetable JuiceschemistryMalusFemaleEnniatinSterigmatocystinToxins
researchProduct

Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis

2018

Background and purpose Late-onset Pompe disease (LOPD) is a rare, multisystem disorder that is well established to mainly impair skeletal muscle function. Systematic studies exploring brain functions in LOPD are lacking. The aim of this study was to detect morphological and functional brain alterations as well as neuropsychological impairment in LOPD. Methods We studied 21 patients (10 male, mean age 49 ± 18.4 years) with defined diagnosis of LOPD, divided into two groups: one with pre-symptomatic hyperCKemia with no muscle weakness and the second with limb-girdle muscle weakness. All patients underwent 3T magnetic resonance imaging (MRI) to obtain morphological/angiographic evaluation as w…

AdultMalemedicine.medical_specialtyAdolescentSmoker scoreNeuropsychological Testscerebrovascular abnormalitieslate-onset Pompe diseaseYoung Adult03 medical and health sciences0302 clinical medicineAtrophyNeuroimagingInternal medicineConnectomemedicinecerebrovascular abnormalities Fazekas score functional magnetic resonance imaging late-onset Pompe disease Pompe disease Smoker score Neurology Neurology (clinical)HumansCognitive Dysfunction030212 general & internal medicineNeuropsychological assessmentAge of OnsetGray MatterAgedmedicine.diagnostic_testGlycogen Storage Disease Type IIbusiness.industryMuscle weaknessPompe diseaseMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance Imagingfunctional magnetic resonance imagingHyperintensityFazekas scoreSuperior frontal gyrusNeurologyBrain sizeCardiologyFemaleNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Cardiac arrhythmias in patients with Danon disease.

2016

Aims Different cardiac arrhythmias have been suggested to be associated with Danon disease, e.g. Wolff–Parkinson–White syndrome. However, a systematic electrophysiological investigation of patients with Danon disease is lacking thus far. Methods and results Seven patients with Danon disease (4 males, 35.8 ± 10.8 years; 3 females, 51.3 ± 19.9 years) from 3 different families were studied. In all patients, the presence of Danon disease was confirmed by western blot of biopsy material or genetic testing. The patients were characterized by 12-lead electrocardiogram (ECG), Holter ECG, echocardiography, and serial implantable cardioverter defibrillator (ICD) interrogations (in ICD recipients). Al…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentElectric CountershockAction Potentials030204 cardiovascular system & hematologyAsymptomaticSudden cardiac death03 medical and health sciencesQRS complex0302 clinical medicineHeart RateRisk FactorsPhysiology (medical)Internal medicineMedicineHumansDanon diseasecardiovascular diseasesPR intervalAgedbusiness.industryCardiac arrhythmiaAtrial fibrillationArrhythmias CardiacMiddle AgedImplantable cardioverter-defibrillatormedicine.diseaseGlycogen Storage Disease Type IIbDefibrillators ImplantablePrimary PreventionDeath Sudden CardiacEchocardiographycardiovascular systemCardiologyAtrioventricular NodeElectrocardiography AmbulatoryFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessElectrophysiologic Techniques Cardiac030217 neurology & neurosurgeryEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
researchProduct

Expanding the clinical spectrum of late-onset Pompe disease: Dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered

2011

Abstract Purpose Cerebro-vascular arteriopathy has been reported in late-onset Pompe disease (LOPD). Evidence of increased aortic stiffness in some patients and smooth muscle involvement in LOPD raises the possibility of aortic involvement. Our aim was to determine if aortic arteriopathy may be a complication of LOPD. Methods One patient with LOPD was diagnosed with aortic dilatation at Duke Metabolic clinic, 4 others were diagnosed at University of Mainz, Germany, where chest X-ray and echocardiography are routinely done for patients. Other causes of aortic vascular disease were assessed. Results We report evidence of dilated arteriopathy involving primarily the ascending thoracic aorta in…

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismAortic DiseasesAorta ThoracicDissection (medical)030204 cardiovascular system & hematologyBiochemistry03 medical and health sciences0302 clinical medicineEndocrinologyBicuspid aortic valveEctasiamedicine.arteryInternal medicineAscending aortaGeneticsmedicineHumansThoracic aortaMolecular BiologyAortaGlycogen Storage Disease Type IIbusiness.industryVascular diseaseMiddle Agedmedicine.disease3. Good healthPhenotypeChild Preschoolcardiovascular systemCardiologyFemaleRadiologyComplicationbusiness030217 neurology & neurosurgeryDilatation PathologicMolecular Genetics and Metabolism
researchProduct

Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoG…

2019

This multicenter/multinational, open-label, ascending-dose study (NCT01898364) evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of repeat-dose avalglucosidase alfa (neoGAA), a second-generation, recombinant acid α-glucosidase replacement therapy, in late-onset Pompe disease (LOPD). Patients ≥18 years, alglucosidase alfa naïve (Naïve) or previously receiving alglucosidase alfa for ≥9 months (Switch), with baseline FVC ≥50% predicted and independently ambulatory, received every-other-week avalglucosidase alfa 5, 10, or 20 mg/kg over 24 weeks. 9/10 Naïve and 12/14 Switch patients completed the study. Avalglucosidase alfa was well-tolerated; no deaths…

Avalglucosidase alfa (neoGAA)0301 basic medicineMaleGLUCOSE TETRASACCHARIDELysosomal acid alpha-glucosidase (GAA) deficiencyCHILDRENPulmonary function testingMOTOR FUNCTION0302 clinical medicineMedicineGenetics (clinical)Late-onset Pompe disease (LOPD)Glycogen Storage Disease Type IIAlglucosidase alfaMOUSE MODELEnzyme replacement therapyMiddle AgedTreatment OutcomeNeurologyTolerabilityEnzyme replacement therapySKELETAL-MUSCLEFemaleLife Sciences & BiomedicineMUSCLE TRAINING RMTGlycogen6-MINUTE WALKmedicine.drugAdultmedicine.medical_specialtyClinical NeurologyGLYCOGEN03 medical and health sciencesFEV1/FVC ratioPharmacokineticsInternal medicineHumansEnzyme Replacement TherapyAdverse effectAlglucosidase alfaScience & Technologybusiness.industryNeurosciencesalpha-GlucosidasesADULTSGlycogen storage disease type IISEVERITY030104 developmental biologyPharmacodynamicsPediatrics Perinatology and Child HealthNeurosciences & NeurologyNeurology (clinical)Glucan 14-alpha-Glucosidasebusiness030217 neurology & neurosurgeryNeuromuscular Disorders
researchProduct

Severe neonatal onset of glycogenosis type IV: Clinical and laboratory findings leading to diagnosis in two siblings

2005

Glycogenosis type IV is an autosomal recessive disease, exceptionally diagnosed at birth: only very few reports of the fatal perinatal neuromuscular form have been described. We report on two sibling male newborns who died at 10 and 4 weeks of age with clinical signs of a systemic storage disease. Prenatal history included polyhydramnios, reduced fetal movements and fetal hydrops, and Caesarean section was performed at 36 weeks of gestational age because of fetal distress. At birth, both babies showed severe hypotonia, hyporeflexia and no spontaneous breathing activity. They never showed active movements, sucking and swallowing and were respirator-dependent until death. A muscle biopsy reve…

Central Nervous SystemMaleCytoplasmPolyhydramniosPathologymedicine.medical_specialtyGenes RecessiveAutopsyNeonatal onsetGlycogen Storage Disease Type IVFatal Outcomeneonate glycogenosis onsetGeneticsFetal distressHumansMedicineTissue DistributionAge of OnsetMuscle SkeletalGenetics (clinical)Family HealthMuscle biopsymedicine.diagnostic_testbusiness.industryInfant NewbornInfantHyporeflexiamedicine.diseaseHypotoniaFetal movementAutopsymedicine.symptombusinessGlycogenJournal of Inherited Metabolic Disease
researchProduct

Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up …

2018

Objective The objective of this study was to evaluate a quantitative method based on conventional T1-weighted magnetic resonance (MR) imaging to assess fatty muscular degeneration in patients with late-onset Pompe disease and to compare it with semi-quantitative visual evaluation (the Mercuri score). In addition, a long-term retrospective data analysis was performed to evaluate treatment response to enzyme replacement therapy with alglucosidase alfa. Methods MR images of the lumbar spine were acquired in 41 patients diagnosed with late-onset Pompe disease from 2006 through 2015. Two independent readers retrospectively evaluated fatty degeneration of the psoas and paraspinal muscles by apply…

MaleSupine position610 Medizinlcsh:MedicineBiochemistry030218 nuclear medicine & medical imagingDiagnostic RadiologyFatschemistry.chemical_compound0302 clinical medicine610 Medical sciencesMedicine and Health SciencesAge of Onsetlcsh:ScienceChildMusculoskeletal SystemObserver VariationMultidisciplinarymedicine.diagnostic_testbiologyGlycogen Storage Disease Type IIPharmaceuticsOrganic Compounds10042 Clinic for Diagnostic and Interventional RadiologyRadiology and ImagingMusclesEnzyme replacement therapyMuscle AnalysisMiddle AgedMagnetic Resonance ImagingLipidsChemistryBioassays and Physiological AnalysisAdipose TissuePhysical SciencesFemaleIntramuscular fatAnatomymedicine.drugResearch ArticleSpirometryAdultmedicine.medical_specialtyAdolescentImaging TechniquesUrologyMuscle Tissue610 Medicine & health1100 General Agricultural and Biological SciencesCreatineResearch and Analysis Methods03 medical and health sciencesYoung AdultDrug TherapyDiagnostic Medicine1300 General Biochemistry Genetics and Molecular BiologymedicineHumansEnzyme Replacement TherapyMuscle SkeletalAlglucosidase alfaAgedRetrospective Studies1000 Multidisciplinarybusiness.industrylcsh:ROrganic ChemistryChemical CompoundsBiology and Life SciencesMagnetic resonance imagingalpha-GlucosidasesCreatineBiological TissuechemistrySkeletal Musclesbiology.proteinlcsh:QCreatine kinasebusiness030217 neurology & neurosurgeryFollow-Up Studies
researchProduct